1.
Long recovery from mass extinction seen
WASHINGTON, July 2 (UPI) -- The U.S. Food and Drug Administration announced approval Thursday of Multaq tablets to help maintain normal heart rhythms in patients with heart disorders.
The FDA said Multaq (dronedarone) is designed to treat atrial fibrillation or atrial flutter in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.
Since Multaq might cause critical adverse reactions, including death, in patients with recent severe heart failure, officials said Multag's drug's label will contain a boxed warning, the FDA's strongest warning, cautioning the drug should not be used by such people.
Multaq is manufactured by the French pharmaceutical company Sanofi-Aventis.
|
|
|
|
|
|
| Additional Science News Stories | |
MIAMI, May 30 (UPI) --
The man who bit off parts of the face of a homeless man in Miami found his victim sleeping in the shade of elevated train tracks, video footage shows.
|
LOS ANGELES, May 30 (UPI) --
Actor Tim Daly said via Twitter his character Pete Wilder won't be on next season of the U.S. medical drama, "Private Practice."
|
ITHACA, N.Y., May 30 (UPI) --
The genome of the tomato has been decoded, a step toward improving yield, nutrition, disease resistance, taste and color of the tomato, U.S. researchers say.
|
TUCSON, May 30 (UPI) --
An Arizona woman said her 8-year-old daughter was humiliated to receive the "Catastrophe Award" from her teacher for giving the most homework excuses.
|
| Stories | Photos | People | Comments |
View Caption
